{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T07:28:02Z","timestamp":1773300482757,"version":"3.50.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,8,15]],"date-time":"2018-08-15T00:00:00Z","timestamp":1534291200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"PLuS Alliance"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Harm Reduct J"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12954-018-0248-4","type":"journal-article","created":{"date-parts":[[2018,8,15]],"date-time":"2018-08-15T08:39:33Z","timestamp":1534322373000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["Beyond cure: patient reported outcomes of hepatitis C treatment among people who inject drugs in Australia"],"prefix":"10.1186","volume":"15","author":[{"given":"Annie","family":"Madden","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Max","family":"Hopwood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanne","family":"Neale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carla","family":"Treloar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,8,15]]},"reference":[{"key":"248_CR1","doi-asserted-by":"publisher","first-page":"637","DOI":"10.7326\/M16-2575","volume":"166","author":"O Falade-Nwulia","year":"2017","unstructured":"Falade-Nwulia O, Suarez-Cuervo C, Nelson D, Fried M, Segal J, Sulkowski M. Oral direct-acting agent therapy for hepatitis C virus infection: a systematic review. Ann Intern Med. 2017;166:637\u201348.","journal-title":"Ann Intern Med"},{"issue":"4","key":"248_CR2","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1053\/j.gastro.2016.08.043","volume":"151","author":"JM Pawlotsky","year":"2016","unstructured":"Pawlotsky JM, Hepatitis C. Drugs: is next generation the last generation? Gastroenterology. 2016;151(4):587\u201390. \n                    https:\/\/doi.org\/10.1053\/j.gastro.2016.08.043\n                    \n                  . Epub 2016\/09\/04. PubMed PMID: 27590791","journal-title":"Gastroenterology"},{"issue":"1 Suppl","key":"248_CR3","doi-asserted-by":"publisher","first-page":"S130","DOI":"10.1016\/j.jhep.2016.07.007","volume":"65","author":"JJ Feld","year":"2016","unstructured":"Feld JJ, Foster GR. Second generation direct-acting antivirals - do we expect major improvements? J Hepatol. 2016;65(1 Suppl):S130\u2013s42. \n                    https:\/\/doi.org\/10.1016\/j.jhep.2016.07.007\n                    \n                  . Epub 2016\/09\/20. PubMed PMID: 27641983","journal-title":"J Hepatol"},{"key":"248_CR4","volume-title":"Combating hepatitis B and C to reach elimination by 2030: advocacy brief","author":"World Health Organisation","year":"2016","unstructured":"World Health Organisation. Combating hepatitis B and C to reach elimination by 2030: advocacy brief. Geneva: World Health Organisation; 2016."},{"key":"248_CR5","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/nrgastro.2013.107","volume":"10","author":"B Hajarizadeh","year":"2013","unstructured":"Hajarizadeh B, Grebely J, Dore G. Epidemiology and natural history of hepatitis C virus infection. Nat Rev Gastroenterol Hepatol. 2013;10:553\u201362.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"6","key":"248_CR6","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1093\/cid\/ciq243","volume":"52","author":"E Gardner","year":"2011","unstructured":"Gardner E, McLees M, Steiner J, Del Rio C, Burman W. The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection. Clin Infect Dis. 2011;52(6):793\u2013800.","journal-title":"Clin Infect Dis"},{"issue":"5","key":"248_CR7","doi-asserted-by":"publisher","first-page":"e97317","DOI":"10.1371\/journal.pone.0097317","volume":"9","author":"BP Linas","year":"2014","unstructured":"Linas BP, Barter DM, Leff JA, Assoumou SA, Salomon JA, Weinstein MC, et al. The hepatitis C cascade of care: identifying priorities to improve clinical outcomes. PLoS One. 2014;9(5):e97317. \n                    https:\/\/doi.org\/10.1371\/journal.pone.0097317\n                    \n                  . Epub 2014\/05\/21. PubMed PMID: 24842841; PubMed Central PMCID: PMCPmc4026319","journal-title":"PLoS One"},{"key":"248_CR8","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.ebiom.2016.08.035","volume":"12","author":"NZ Janjua","year":"2016","unstructured":"Janjua NZ, Kuo M, Yu A, Alvarez M, Wong S, Cook D, et al. The population level cascade of care for hepatitis C in British Columbia, Canada:the BC hepatitis testers cohort (BC-HTC). EBioMedicine. 2016;12:189\u201395. \n                    https:\/\/doi.org\/10.1016\/j.ebiom.2016.08.035\n                    \n                  .","journal-title":"EBioMedicine"},{"key":"248_CR9","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.drugpo.2017.03.015","volume":"47","author":"M Harris","year":"2017","unstructured":"Harris M. Managing expense and expectation in a treatment revolution: problematizing prioritisation through an exploration of hepatitis C treatment 'benefit'. Int J Drug Policy. 2017;47:161\u20138. \n                    https:\/\/doi.org\/10.1016\/j.drugpo.2017.03.015\n                    \n                  . Epub 2017\/04\/30. PubMed PMID: 28455145","journal-title":"Int J Drug Policy"},{"issue":"6","key":"248_CR10","doi-asserted-by":"publisher","first-page":"555","DOI":"10.3109\/09638237.2012.734653","volume":"22","author":"J Trujols","year":"2013","unstructured":"Trujols J, Portella MJ, Iraurgi I, Campins MJ, Si\u00f1ol N. Cobos JPdL. Patient-reported outcome measures: are they patient-generated, patient-centred or patient-valued? J Ment Health. 2013;22(6):555\u201362. \n                    https:\/\/doi.org\/10.3109\/09638237.2012.734653\n                    \n                  .","journal-title":"J Ment Health"},{"key":"248_CR11","unstructured":"Greenhalgh J, Dalkin S, Gooding K, Gibbons E, Wright J, Meads D, et al. Health Services and Delivery Research. Functionality and feedback: a realist synthesis of the collation, interpretation and utilisation of patient-reported outcome measures data to improve patient care. Southampton (UK): NIHR Journals Library Copyright (c) Queen's Printer and Controller of HMSO 2017. This work was produced by Greenhalgh et al. under the terms of a commissioning contract issued by the secretary of state for health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR journals library, National Institute for Health Research, evaluation, trials and studies coordinating entre, alpha house, University of Southampton Science Park, Southampton SO16 7NS, UK.; 2017."},{"issue":"2","key":"248_CR12","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1056\/NEJMp1611252","volume":"376","author":"E Basch","year":"2017","unstructured":"Basch E. Patient-reported outcomes - harnessing patients' voices to improve clinical care. N Engl J Med. 2017;376(2):105\u20138. \n                    https:\/\/doi.org\/10.1056\/NEJMp1611252\n                    \n                  . Epub 2017\/01\/12. PubMed PMID: 28076708","journal-title":"N Engl J Med"},{"key":"248_CR13","volume-title":"Patient-reported outcome measures: literature review","author":"K Williams","year":"2016","unstructured":"Williams K, Sansoni J, Morris D, Grootemaat P, Thompson C. Patient-reported outcome measures: literature review. Sydney: ACSQHC; 2016."},{"key":"248_CR14","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1146\/annurev-med-010713-141500","volume":"65","author":"E Basch","year":"2014","unstructured":"Basch E. New frontiers in patient-reported outcomes: adverse event reporting, comparative effectiveness, and quality assessment. Annu Rev Med. 2014;65:307\u201317. \n                    https:\/\/doi.org\/10.1146\/annurev-med-010713-141500\n                    \n                  . Epub 2013\/11\/28. PubMed PMID: 24274179","journal-title":"Annu Rev Med"},{"key":"248_CR15","doi-asserted-by":"publisher","unstructured":"Black N. Patient reported outcome measures could help transform healthcare. BMJ : Br Med J. 2013;346 \n                    https:\/\/doi.org\/10.1136\/bmj.f167\n                    \n                  .","DOI":"10.1136\/bmj.f167"},{"key":"248_CR16","volume-title":"Research methods for health and social care","author":"J Dawson","year":"2009","unstructured":"Dawson J. Measuring health status. In: Neale J, editor. Research methods for health and social care. London: Palgrave; 2009."},{"key":"248_CR17","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.drugalcdep.2009.06.016","volume":"105","author":"L Brener","year":"2009","unstructured":"Brener L, Resnick I, Ellard J, Treloar C, Bryant J. Exploring the role of consumer participation in drug treatment. Drug Alcohol Depend. 2009;105:172\u20135.","journal-title":"Drug Alcohol Depend"},{"issue":"2","key":"248_CR18","first-page":"85","volume":"20","author":"C Lloyd","year":"2013","unstructured":"Lloyd C. The stigmatization of problem drug users: a narrative literature review. Drugs: Educ, Prev Policy. 2013;20(2):85\u201395.","journal-title":"Drugs: Educ, Prev Policy"},{"key":"248_CR19","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.drugalcdep.2006.10.014","volume":"88","author":"J Ahern","year":"2007","unstructured":"Ahern J, Stuber J, Galea S. Stigma, discrimination and the health of illicit drug users. Drug Alcohol Depend. 2007;88:188\u201396.","journal-title":"Drug Alcohol Depend"},{"key":"248_CR20","first-page":"Art.30","volume-title":"Participatory Research Methods: A Methodological Approach in Motion [110 paragraphs]. Forum Qualitative Sozialforschung\/Forum: Qualitative Social Research","author":"J Bergold","year":"2012","unstructured":"Bergold J, Thomas S. Participatory Research Methods: A Methodological Approach in Motion [110 paragraphs]. Forum Qualitative Sozialforschung\/Forum: Qualitative Social Research. 2012;31(1):Art.30."},{"issue":"3","key":"248_CR21","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1177\/1476750309336715","volume":"7","author":"P Wicks","year":"2009","unstructured":"Wicks P, Reason P. Initiating action research: challenges and paradoxes of opening communicative space. Action Res. 2009;7(3):243\u201362.","journal-title":"Action Res"},{"issue":"2","key":"248_CR22","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1191\/1478088706qp063oa","volume":"3","author":"V Braun","year":"2006","unstructured":"Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol. 2006;3(2):77\u2013101.","journal-title":"Qual Res Psychol"},{"issue":"1","key":"248_CR23","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s12879-015-0748-8","volume":"15","author":"J Smith-Palmer","year":"2015","unstructured":"Smith-Palmer J, Cerri K, Valentine W. Achieving sustained virologic response in hepatitis C: a systematic review of the clinical, economic and quality of life benefits. BMC Infect Dis. 2015;15(1):19. \n                    https:\/\/doi.org\/10.1186\/s12879-015-0748-8\n                    \n                  .","journal-title":"BMC Infect Dis"},{"issue":"3","key":"248_CR24","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1111\/apt.13269","volume":"42","author":"ZM Younossi","year":"2015","unstructured":"Younossi ZM, Stepanova M, Nader F, Lam B, Hunt S. The patient's journey with chronic hepatitis C from interferon plus ribavirin to interferon- and ribavirin-free regimens: a study of health-related quality of life. Aliment Pharmacol Ther. 2015;42(3):286\u201395. \n                    https:\/\/doi.org\/10.1111\/apt.13269\n                    \n                  .","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"248_CR25","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1177\/1359105310370499","volume":"16","author":"M Hopwood","year":"2010","unstructured":"Hopwood M, Nakamura T, Treloar C. Disclosing hepatitis C infection within everyday contexts: implications for accessing support and healthcare. J Health Psychol. 2010;16(6):811\u20138.","journal-title":"J Health Psychol"},{"key":"248_CR26","volume-title":"C-Change: Report of the enquiry into hepatitis C related discrimination","author":"Anti-Discrimination Board of New South Wales","year":"2001","unstructured":"Anti-Discrimination Board of New South Wales. C-Change: Report of the enquiry into hepatitis C related discrimination. Sydney: Anti-Discrimination Board of New South Wales; 2001."},{"key":"248_CR27","doi-asserted-by":"publisher","first-page":"87","DOI":"10.2307\/4065273","volume":"2","author":"N Crofts","year":"1997","unstructured":"Crofts N, Louie R, Loff B. The next plague: stigmatization and discrimination related to hepatitis C virus infection in Australia. Health Hum Rights. 1997;2:87\u201396.","journal-title":"Health Hum Rights"},{"issue":"4","key":"248_CR28","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1080\/08870446.2011.592982","volume":"27","author":"M Fry","year":"2012","unstructured":"Fry M, Bates G. The tasks of self-managing hepatitis C: the significance of disclosure. Psychol Health. 2012;27(4):460\u201374. \n                    https:\/\/doi.org\/10.1080\/08870446.2011.592982\n                    \n                  . Epub 2011\/07\/09. PubMed PMID: 21736430","journal-title":"Psychol Health"},{"key":"248_CR29","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1080\/09595230500102434","volume":"24","author":"R Room","year":"2005","unstructured":"Room R. Stigma, social inequality and alcohol and drug use. Drug Alcohol Rev. 2005;24:143\u201355.","journal-title":"Drug Alcohol Rev"},{"key":"248_CR30","volume-title":"Purity and danger: an analysis of the concepts of pollution and taboo","author":"M Douglas","year":"1994","unstructured":"Douglas M. Purity and danger: an analysis of the concepts of pollution and taboo. London: Routledge; 1994."},{"issue":"4","key":"248_CR31","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1080\/09540120120057950","volume":"13","author":"CM Roy","year":"2001","unstructured":"Roy CM, Cain R. The involvement of people living with HIV\/AIDS in community-based organizations: contributions and constraints. AIDS Care. 2001;13(4):421\u201332. \n                    https:\/\/doi.org\/10.1080\/09540120120057950\n                    \n                  .","journal-title":"AIDS Care"},{"issue":"3","key":"248_CR32","doi-asserted-by":"publisher","first-page":"201","DOI":"10.3109\/10826088709027425","volume":"22","author":"SR Friedman","year":"1987","unstructured":"Friedman SR, Des Jarlais DC, Sotheran JL, Garber J, Cohen H, Smith D. AIDS and self-organization among intravenous drug users. Int J Addict. 1987;22(3):201\u201319. Epub 1987\/03\/01. PubMed PMID: 3583474","journal-title":"Int J Addict"},{"issue":"1","key":"248_CR33","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1111\/j.1533-8525.2002.tb02383.x","volume":"43","author":"N Wieloch","year":"2002","unstructured":"Wieloch N. Collective mobilization and identity from the underground: the deployment of \u201coppositional capital\u201d in the harm reduction movement. Sociol Q. 2002;43(1):45\u201372. \n                    https:\/\/doi.org\/10.1111\/j.1533-8525.2002.tb02383.x\n                    \n                  .","journal-title":"Sociol Q"},{"issue":"3","key":"248_CR34","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1521\/aeap.2014.26.3.234","volume":"26","author":"A Madden","year":"2014","unstructured":"Madden A, Wodak A. Australia\u2019s response to HIV among people who inject drugs. AIDS Educ Prev. 2014;26(3):234\u201344.","journal-title":"AIDS Educ Prev"},{"issue":"supp 2","key":"248_CR35","first-page":"22","volume":"76","author":"W Dowdle","year":"1998","unstructured":"Dowdle W. The principles of disease elimination and eradication. Bull World Health Organ. 1998;76(supp 2):22\u20135.","journal-title":"Bull World Health Organ"},{"issue":"5","key":"248_CR36","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1016\/j.jhep.2016.01.001","volume":"64","author":"H Midgard","year":"2016","unstructured":"Midgard H, Bjoro B, Maeland A, Konopski Z, Kileng H, Damas JK, et al. Hepatitis C reinfection after sustained virological response. J Hepatol. 2016;64(5):1020\u20136. \n                    https:\/\/doi.org\/10.1016\/j.jhep.2016.01.001\n                    \n                  . Epub 2016\/01\/19. PubMed PMID: 26780289","journal-title":"J Hepatol"},{"key":"248_CR37","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.drugalcdep.2016.05.012","volume":"165","author":"A Weir","year":"2016","unstructured":"Weir A, McLeod A, Innes H, Valerio H, Aspinall EJ, Goldberg DJ, et al. Hepatitis C reinfection following treatment induced viral clearance among people who have injected drugs. Drug Alcohol Depend. 2016;165:53\u201360. \n                    https:\/\/doi.org\/10.1016\/j.drugalcdep.2016.05.012\n                    \n                  . Epub 2016\/06\/09. PubMed PMID: 27268294","journal-title":"Drug Alcohol Depend"},{"issue":"8","key":"248_CR38","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1111\/jvh.12183","volume":"21","author":"C Treloar","year":"2014","unstructured":"Treloar C, Rance J, Dore G, Grebely J. Barriers and facilitators of hepatitis C care and treatment uptake in opioid treatment programs: the ETHOS study in NSW, Australia. J Viral Hepat. 2014;21(8):560\u20137.","journal-title":"J Viral Hepat"},{"issue":"4","key":"248_CR39","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/j.jhep.2016.06.015","volume":"65","author":"F Conti","year":"2016","unstructured":"Conti F, Buonfiglioli F, Scuteri A, Crespi C, Bolondi L, Caraceni P, et al. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals. J Hepatol. 2016;65(4):727\u201333. \n                    https:\/\/doi.org\/10.1016\/j.jhep.2016.06.015\n                    \n                  .","journal-title":"J Hepatol"},{"issue":"9","key":"248_CR40","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1177\/1049732309341656","volume":"19","author":"C Treloar","year":"2009","unstructured":"Treloar C, Rhodes T. The lived experience of hepatitis C and its treatment among injecting drug users: qualitative synthesis. Qual Health Res. 2009;19(9):1321\u201334.","journal-title":"Qual Health Res"},{"issue":"3","key":"248_CR41","doi-asserted-by":"publisher","first-page":"215","DOI":"10.7326\/M15-0406","volume":"163","author":"S Barua","year":"2015","unstructured":"Barua S, Greenwald R, Grebely J, Dore GJ, Swan T, Taylor LE. Restrictions for medicaid reimbursement of Sofosbuvir for the treatment of hepatitis C virus infection in the United States. Ann Intern Med. 2015;163(3):215\u201323. \n                    https:\/\/doi.org\/10.7326\/m15-0406\n                    \n                  . Epub 2015\/06\/30PubMed PMID: 26120969","journal-title":"Ann Intern Med"},{"issue":"4","key":"248_CR42","doi-asserted-by":"publisher","first-page":"E605","DOI":"10.9778\/cmajo.20160008","volume":"4","author":"A Marshall","year":"2016","unstructured":"Marshall A, Saeed S, Barrett L, Cooper C, Treloar C, Bruneau J, et al. Restrictions for reimbursement of direct-acting antiviral treatment for hepatitis C virus infection in Canada: a descriptive study. CMAJ Open. 2016;4(4):E605\u2013E14.","journal-title":"CMAJ Open"},{"issue":"2","key":"248_CR43","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/S2468-1253(17)30284-4","volume":"3","author":"AD Marshall","year":"2018","unstructured":"Marshall AD, Cunningham EB, Nielsen S, Aghemo A, Alho H, Backmund M, et al. Restrictions for reimbursement of interferon-free direct-acting antiviral drugs for HCV infection in Europe. Lancet Gastroenterol Hepatol. 2018;3(2):125\u201333. \n                    https:\/\/doi.org\/10.1016\/S2468-1253(17)30284-4\n                    \n                  .","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"248_CR44","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1111\/j.1467-842X.1997.tb01643.x","volume":"21","author":"J Hepworth","year":"1997","unstructured":"Hepworth J, Krug G. Hepatitis C and policy implementation: ethics as a dialogic process for resource allocation [editorial]. Aust N Z J Public Health. 1997;21(1):4\u20137.","journal-title":"Aust N Z J Public Health"},{"issue":"1","key":"248_CR45","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1177\/1359105313500249","volume":"19","author":"D Rose","year":"2014","unstructured":"Rose D. Patient and public involvement in health research: ethical imperative and\/or radical challenge? J Health Psychol. 2014;19(1):149\u201358. \n                    https:\/\/doi.org\/10.1177\/1359105313500249\n                    \n                  . Epub 2013\/09\/24, PubMed PMID: 24058120","journal-title":"J Health Psychol"}],"container-title":["Harm Reduction Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-018-0248-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12954-018-0248-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-018-0248-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,14]],"date-time":"2019-08-14T19:19:17Z","timestamp":1565810357000},"score":1,"resource":{"primary":{"URL":"https:\/\/harmreductionjournal.biomedcentral.com\/articles\/10.1186\/s12954-018-0248-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,15]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["248"],"URL":"https:\/\/doi.org\/10.1186\/s12954-018-0248-4","relation":{},"ISSN":["1477-7517"],"issn-type":[{"value":"1477-7517","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,15]]},"assertion":[{"value":"9 May 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This evaluation received approval from the human research ethics committees of UNSW, Sydney (HC16706).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"42"}}